{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:54:04Z","timestamp":1781758444060,"version":"3.54.5"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Late relapse after allogeneic hematopoietic cell transplantation (HCT) with phenotypic and molecular divergence from the original leukemia is rare. We describe a 60-year-old man with FLT3-ITD\u2013mutated acute myeloid leukemia (AML) who achieved durable remission following venetoclax-based therapy and a combined HLA-matched sibling HCT\u2013kidney transplant with FLT3 inhibitor maintenance. Four years post-transplant, he developed chronic myelomonocytic leukemia (CMML-1) characterized by re-emergence of driver mutations without FLT3-ITD, marked loss of donor myeloid chimerism, preserved donor T-cell chimerism, and sustained renal allograft function. This case highlights a unique clinical circumstance that may function to recontextualize myelomonocytic features in AML: that they can be attributed to acute leukemias arising from clonal hematopoiesis or occult chronic malignancies, as opposed to de novo AML, particularly given the difficulty in differentiating the two in the acute leukemic setting.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag213","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:21:04Z","timestamp":1780312864000},"source":"Crossref","is-referenced-by-count":0,"title":["Recrudescence of a FLT3 wild-type CMML clone after allogeneic stem cell transplant for FLT3-ITD acute myeloid leukemia"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-5330","authenticated-orcid":false,"given":"Hatem A","family":"Ellaithy","sequence":"first","affiliation":[{"name":"Hematopoietic Cell Transplant & Cell Therapy Program, Mass General Brigham Cancer Institute , Boston, MA, 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital , Boston, MA, Boston, MA, 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B","family":"Hergott","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital , Boston, MA, 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant & Cell Therapy Program, Mass General Brigham Cancer Institute , Boston, MA, 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026061800213310300_oyag213-B1","doi-asserted-by":"publisher","first-page":"6471901","DOI":"10.1155\/2016\/6471901","article-title":"Combined bone marrow and kidney transplantation for the induction of specific tolerance","volume":"2016","author":"Chen","year":"2016","journal-title":"Adv Hematol"},{"key":"2026061800213310300_oyag213-B2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"key":"2026061800213310300_oyag213-B3","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood."},{"key":"2026061800213310300_oyag213-B4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s12094-021-02585-x","article-title":"Mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"23","author":"Jian","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2026061800213310300_oyag213-B5","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","article-title":"Structural and functional alterations of FLT3 in acute myeloid leukemia","volume":"15","author":"Meshinchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026061800213310300_oyag213-B6","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.celrep.2013.04.031","article-title":"FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors","volume":"3","author":"Mead","year":"2013","journal-title":"Cell Rep"},{"key":"2026061800213310300_oyag213-B7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"key":"2026061800213310300_oyag213-B8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell."},{"key":"2026061800213310300_oyag213-B9","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061800213310300_oyag213-B10","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1182\/blood-2024-197986","article-title":"Estimating the prevalence of possible undiagnosed chronic myelomonocytic leukemia in the general population: an Nhanes analysis","volume":"144","author":"Sastow","year":"2024","journal-title":"Blood"},{"key":"2026061800213310300_oyag213-B11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/cancers17071229","article-title":"Usefulness of flow cytometry monocyte partitioning in the diagnosis of chronic myelomonocytic leukemia in a real-world setting","volume":"17","author":"Liu","year":"2025","journal-title":"Cancers (Basel)."},{"key":"2026061800213310300_oyag213-B12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood."},{"key":"2026061800213310300_oyag213-B13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cancers16071419","article-title":"Late relapse after allogeneic stem cell transplantation in patients treated for acute myeloid leukemia: relapse incidence, characteristics, role of conditioning regimen, and outcome","volume":"16","author":"Antier","year":"2024","journal-title":"Cancers (Basel)."},{"key":"2026061800213310300_oyag213-B14","doi-asserted-by":"publisher","first-page":"362.e1","DOI":"10.1016\/j.jtct.2023.02.020","article-title":"Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC","volume":"29","author":"Kaphan","year":"2023","journal-title":"Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther"},{"key":"2026061800213310300_oyag213-B15","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1182\/blood.2023023476","article-title":"Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee","volume":"143","author":"Onida","year":"2024","journal-title":"Blood."},{"key":"2026061800213310300_oyag213-B16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia."},{"key":"2026061800213310300_oyag213-B17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia."},{"key":"2026061800213310300_oyag213-B18","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"key":"2026061800213310300_oyag213-B19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12185-017-2243-z","article-title":"CMML: Clinical and molecular aspects","volume":"105","author":"Itzykson","year":"2017","journal-title":"Int J Hematol"},{"key":"2026061800213310300_oyag213-B20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"key":"2026061800213310300_oyag213-B21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/ehm.10.32","article-title":"Relapse after allogeneic stem cell transplantation","volume":"3","author":"Barrett","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"2026061800213310300_oyag213-B22","doi-asserted-by":"publisher","first-page":"265.e1","DOI":"10.1016\/j.jtct.2022.12.006","article-title":"Outcomes in patients with FLT3-Mutated relapsed\/ refractory acute myelogenous leukemia who underwent transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy","volume":"29","author":"Perl","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026061800213310300_oyag213-B23","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","article-title":"Compassionate use of sorafenib in FLT3-ITD\u2013positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation","volume":"113","author":"Metzelder","year":"2009","journal-title":"Blood."},{"key":"2026061800213310300_oyag213-B24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40164-025-00652-5","article-title":"Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study","volume":"14","author":"Zugasti","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026061800213310300_oyag213-B25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood-2023-181795","article-title":"Venetoclax (VEN) improves response rates but not survival in patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents (HMA): a multicenter, propensity score analysis","volume":"142","author":"Tremblay","year":"2023","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag213\/68457133\/oyag213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag213\/68457133\/oyag213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag213\/68457133\/oyag213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:21:41Z","timestamp":1781756501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag213\/8700286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag213","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,2]]},"article-number":"oyag213"}}